Two Countries You Might Be Surprised to Find Hallgarten's Chris Ecclestone Likes Now
Source: Kevin Michael Grace of The Gold Report  (12/15/14)
How tight is money in the mining industry? So much so, according to Chris Ecclestone, mining strategist with Hallgarten & Co., that juniors are punished for resource estimates because the market believes they can't afford to develop their properties further. In this interview with The Gold Report, Ecclestone explains that canny juniors are choosing past-producing properties, which boast dependable resources estimated by majors and already existing infrastructure. And he names two current gold producers he believes are woefully undervalued. More >

The Copper Denominator: Gianni Kovacevic
Source: J. Alec Gimurtu of The Gold Report  (12/15/14)
Gianni Kovacevic, the author of "My Electrician Drives a Porsche?" and executive chairman of CopperBank Resources Corp., takes a scientific view of historical, social and environmental trends in energy usage and identifies copper as the common denominator. As global energy usage increases, most of that energy flows through copper. In this interview with The Gold Report, Kovacevic discusses how his book explains his approach in understanding copper's investment opportunity in a scientific context, and the role of the company he founded to take advantage of this secular trend. More >

BioPharm Executive: Top 7 Trends of 2014, with Predictions for 2015
Source: Karl Thiel, BioSpace.com  (12/15/14)
"The cancer immunotherapy area will heat up further. . .And while there won't be rush of approvals for RNAi, antisense, and gene therapy drugs in 2015, we'll get data that puts us a lot closer." More >

Wedbush Securities' David Nierengarten on Genetic Cures for Disease: Impossible Dream Come True?
Source: George S. Mack of The Life Sciences Report  (12/11/14)
Clinicians like to speak in terms of "managing" disease. That term of art is an admission that, in most cases, they can't cure the serious problems confronting patients. In this interview with The Life Sciences Report, David Nierengarten of Wedbush Securities explores gene therapies that actually correct an inborn mutation in human DNA, creating permanent change, actual cures and better lives for patients. It sounds beyond the reach of medicine. . .and therein lies the opportunity: Investors in gene therapy companies may capture serious returns on risk capital when the cure is attained. More >

Chen Lin: Low Oil Prices Fuel Bonanza Increases in Ethanol Stocks
Source: Kevin Michael Grace of The Energy Report  (12/11/14)
Chen Lin was one of the very few who foresaw the collapse in oil prices, so investors are well advised to pay attention to his advice. In this interview with The Energy Report,
the author of the What is Chen Buying? What is Chen Selling? newsletter touts the prospects of a few oil companies that can prosper in the downturn, and explains why cheap oil means high profits for U.S. ethanol producers. More >

Elliott Wave Charts Point to Shocking Countertrend for Gold: Steven Hochberg
Source: JT Long of The Gold Report  (12/10/14)
It's not just surfers who scrutinize wave patterns. Steven Hochberg, chief market analyst at Elliott Wave International, uses the Wave Principle to predict the movements of commodities and the stock market based on a number of factors, including sentiment. In this interview with The Gold Report, he reads the waves and sees indications that the stock market is headed for a downtrend, while commodities will move up, although not in a direct line.
More >

7 Companies 'Best Positioned to Deliver in 2015'
Source: Teresa Matich, Resource Investing News  (12/10/14)
"Despite the volatile market, there's definitely still some silver lining out there." More >

Rob Chang Spins Yellowcake into Gold and Gold into Green
Source: Peter Byrne of The Mining Report  (12/9/14)
The long winter of falling uranium prices is about to give way to a Japanese spring. In an interview with The Mining Report, Cantor Fitzgerald's Rob Chang discusses the return of the small producers as an increasingly hungry market looks to eat up all of the available uranium. Plus, Chang likes gold and enlightens us on how gold miners are shaking profits out of slag. More >

Robert Baylis: A Taste for Tungsten—Finding the Sweet Spot for Investors
Source: Brian Sylvester of The Gold Report  (12/8/14)
Finding the right combination of factors for an investable tungsten operation is no easy matter, says Robert Baylis, managing director of London-based Roskill. Much of the tungsten space is held privately, but some publicly traded equities offer leverage to future demand growth. In this interview with The Gold Report, Baylis says investor success in this space depends on finding that sweet spot where low capital and operating costs act as the honey needed to lure end users into offtake agreements or outright takeovers. More >

Gold Shorting Exhaustion
Source: Adam Hamilton, Zeal Intelligence  (12/6/14)
"Short selling always runs in relatively short spurts, ramping up fast but quickly peaking in selling exhaustion. And I suspect that's exactly what's happening in gold now." More >

Could Pinky the 'Super Mouse' End Alzheimer's?
Source: Ray Blanco, The Daily Reckoning  (12/5/14)
What would happen if you took Pinky and swapped some of his brain cells with human ones? As it turns out, what you might get is a really smart mouse. But that's not all you'd get. You'd get a potential new therapy, capable of curing Alzheimer's, Lou Gehrig's disease. . .even multiple sclerosis. More >

Micro-Cap E&Ps with Less Risky Businesses: Casimir's Philip Juskowicz
Source: Brian Sylvester of The Energy Report  (12/4/14)
Many small-cap exploration and production companies have had a good run in recent years, but are now getting whacked given their strong connections to oil prices. But the news is not all bad: Philip Juskowicz of Casimir Capital makes a good case for certain micro-cap names. In this exclusive interview with The Energy Report, Juskowicz discusses four companies with strong narratives, two with defensive assets, and notes that natural gas names could see market love as margins widen. More >

Brinson Patrick's Christopher S. James: All Catalysts Are Not Created Equal
Source: George S. Mack of The Life Sciences Report  (12/4/14)
Why do some good-news milestones cause stocks to languish, or even fall? Neurosurgeon Christopher James, managing director and senior biotechnology analyst at Brinson Patrick Securities, performs due diligence on stocks, in part, by connecting his clinical experience to the readiness of physicians and patients to adopt new therapies. In this interview with The Life Sciences Report, James gives real-life examples of catalysts and their effects, and highlights three strong biotech plays that could return multiples of invested capital. More >

Doug Loud and Jeff Mosseri Say Gold Will Regain Its Shine in 2015
Source: Kevin Michael Grace of The Gold Report  (12/3/14)
For all the talk of gold sinking remorselessly to $1,000 an ounce, the metal has risen to $1,200 per ounce and has held its ground. Have we seen the bottom? Money managers Doug Loud and Jeff Mosseri of Greystone Asset Management say that if we haven't seen the bottom, we will soon. In this interview with The Gold Report, they predict that the next bull market will result in patient investors realizing gains in the multiples and suggest several companies poised to break out. More >

Harsh Words on Swiss Gold Referendum
Source: Lawrence Williams, Mineweb  (12/3/14)
"Egon von Greyerz is a firm believer that gold is underpriced at the moment—primarily because it is now so out of sync with the huge amounts of debt built up by governments around the world and the huge amount of money printing to preserve the perception that economies are stable to positive by keeping interest rates at or near zero." More >

Reactors Restart Uranium Mines: Thomas Drolet
Source: Peter Byrne of The Mining Report  (12/2/14)
Thomas Drolet has decades of experience in capitalizing on the movement of international energy markets. The chief of Drolet & Associates Energy Services is not sanguine about the long-term potential of fracking, but in this interview with The Mining Report, he tells us why now is a great time to reinvest in the uranium space. More >

Cowboy Up for a Biotech Stock Winner Has Wall Street Fooled
Source: Michael Robinson, Money Morning  (12/2/14)
"Sovaldi sales are slowing down for a simple but lucrative reason. Gilead Sciences is set to release a new drug that will soon replace this blockbuster—and that may do even better." More >

As Excitement Builds in the Montney, Companies Seek More Infrastructure
Source: James Stafford, OilPrice.com  (12/2/14)
"Even with significant oil and gas reserves trapped in shale, a variety of factors need to come together to turn a given region into a significant producer." More >

Jordan Roy-Byrne Believes 2015 Will See the Renewal of Gold's Secular Bull Market
Source: Kevin Michael Grace of The Gold Report  (12/1/14)
Past performance does not guarantee future performance, as they say, but Jordan Roy-Byrne, CMT, editor and publisher of The Daily Gold Premium, is persuaded that the bottom in gold is no more than a couple of months away. And after that, look out. In this interview with The Gold Report, Roy-Byrne says that his study of gold's history explains why gold could retest $1,900 per ounce by the end of 2016 before going parabolic. More >

Taking Multiple Shots on the Cancer Treatment Goal: Rexahn's Peter Suzdak
Source: George S. Mack of The Life Sciences Report  (11/28/14)
Rexahn Pharmaceuticals Inc.'s cancer-fighting drug development platform is built on a theme that focuses on targets exclusive to tumor cells—the ultimate strategy in the silver-bullet theory of dealing with disease because it can increase efficacy while reducing off-target effects, including heart and liver toxicity. Moreover, lower toxicity enables higher drug doses, which could enhance the desired therapeutic effects. In this interview with The Life Sciences Report, Rexahn CEO Peter D. Suzdak, Ph.D. talks about his company's clinical-stage drug candidates, and links their mechanisms of action to the ultimate value proposition for owning company shares. More >

Harry Dent's Simple Strategy for Surviving Withdrawals from 'Markets on Crack'
Source: JT Long of The Gold Report  (11/26/14)
An aging world is a deflationary one, according to "The Demographic Cliff" author Harry Dent. In this interview with The Gold Report, he predicts a major, painful crash in the next two years based on population statistics and historic patterns. He has some positive short-term predictions for gold, and investment suggestions for how to be one of the ones still standing after the dust settles. More >

Gold Investing Myths: What Gold's Critics Don't Get
Source: Jim Bach, Money Morning  (11/26/14)
"In the right allocations gold is an important part of a healthy portfolio. It can hedge against market crisis and provide returns when other assets underperform." More >

So Bad It's Good: Surviving 2014
Source: JT Long of Streetwise Reports  (11/25/14)
As we approach Thanksgiving in the States, Streetwise Reports
reached out to some of our most popular experts for perspective on the natural resource market during this volatile time. While some thought 2014 was so bad it was good—for contrarian investors—others will be all too happy to see the year in the rearview mirror. More >

Smart Oil is Cheap Oil: Rudolf Hokanson
Source: Peter Byrne of The Energy Report  (11/25/14)
Even a global economic growth slowdown will not seriously impact the future of the shale oil patch, Rudolf "Rudy" Hokanson tells The Energy Report. The Barrington Research analyst's job is to think long and hard about the target prices he assigns to the best and brightest junior firms playing in the Bakken and other shales. He likes smart managers—the ones who know how to reduce costs at the wellhead while improving the flow of oil, gas, and liquids—and provides the names of companies with such managers at the helm. More >

Rolling with Biotech's Regulatory Punches: Chen Lin
Source: Peter Byrne of The Life Sciences Report  (11/25/14)
Being temporarily burned by the U.S. Food and Drug Administration can be a mixed blessing for a biotech with a good product in the pipeline. In an interview with The Life Sciences Report, Chen Lin, publisher of the investor newsletter What is Chen Buying? What is Chen Selling?, explains how to make money on biotech trades in sync with both the good regulatory news and the bad. More >